INAB
IN8BIO, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.08
+0.93%Sep 18, 2026, 13:38 UTC
IN8bio hired Oxana Polyakova as senior vice president of research & development; she previously served as chief scientific officer at LAVA Therapeutics.
Source:Jun 1, 2026, 00:00 UTC
IN8BIO, Inc. terminated its Controlled Equity Offering Sales Agreement with Cantor Fitzgerald, effective May 29, 2026.
Jun 1, 2026, 00:00 UTC
IN8BIO, Inc. entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC to sell common stock from time to time in an at-the-market offering.